Table 2.

Univariate and multivariate analysis of survival in patients with HCC.

	Univariate analysis			Multivariate analysis
Clinicopathological factors	HR	95% CI	P	HR	95% CI	P
OS
Gender	0.78	0.54–1.13	.186
Age	1.01	1.00–1.03	.075
T stage	1.66	1.37–2.00	<.001	1.23	0.65–2.32	.520
Clinical stage	1.64	1.34–2.01	<.001	1.28	0.67–2.46	.454
Histologic grade	1.13	0.89–1.45	.324
TPX2 expression	1.86	1.29–2.69	.001	1.66	1.13–2.45	.011
PFS
Gender	1.00	0.72–1.38	.977
Age	1.00	0.98–1.01	.478
T stage	1.60	1.37–1.88	<.001	0.86	0.49–1.51	.603
Clinical stage	1.65	1.38–1.92	<.001	1.84	1.04–3.25	.038
Histologic grade	1.13	0.92–1.39	.244
TPX2 expression	1.86	1.36–2.54	<.001	1.66	1.20–2.29	.002
DFS
Gender	1.18	0.82–1.71	.370
Age	1.00	0.98–1.01	.610
T stage	1.65	1.36–2.00	<.001	0.96	0.46–2.02	.958
Clinical stage	1.68	1.36–2.06	<.001	1.69	0.79–3.61	.176
Histologic grade	1.21	0.97–1.53	.099
TPX2 expression	1.72	1.22–2.43	.002	1.56	1.09–2.23	.016
DSS
Gender	0.85	0.53–1.37	.510
Age	1.00	0.99–1.02	.748
T stage	2.01	1.58–2.55	<.001	1.15	0.57–2.32	.691
Clinical stage	2.02	1.54–2.65	<.001	1.65	0.81–3.37	.170
Histologic grade	1.13	0.82–1.54	.464
TPX2 expression	2.73	1.66–4.49	<.001	2.51	1.45–4.33	.001

95% CI = 95% confidence interval, DFS = disease-free survival, DSS = disease-specific survival, HR = hazard ratio, OS = overall survival, PFS = progression-free survival, TPX2 = targeting protein for Xenopus kinesin-like protein 2.

Bold values indicated statistical significance.